A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

Stopped early · Phase 1

Conditions studied: Multiple Myeloma

In brief

The purpose of this study is to determine the recommended dose and schedule, and evaluate the safety and preliminary efficacy of alnuctamab in combination with mezigdomide in participants with relapsed and/or refractory multiple myeloma.

Key facts

Study ID

NCT06163898

Run by

Celgene

People needed

4

Starts

2024-02-27

Expected to finish

2025-06-03

Last updated by the study team

2026-04-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant has a history of RRMM, and must:
• Part A: Have previously received ≥ 3 prior lines of anti-myeloma therapy.
• Part B and Part C: Have received 1 to 3 prior lines of anti-myeloma therapy.

You may not qualify if…

• Must not have previously received alnuctamab or mezigdomide.
• Note: Other protocol-defined inclusion/exclusion criteria apply

Where it is running

• Local Institution - 0033 — Birmingham, Alabama, United States
• Local Institution - 0035 — New Haven, Connecticut, United States
• Local Institution - 0018 — New York, New York, United States
• Local Institution - 0021 — Petah Tikva, Central District, Israel
• Local Institution - 0030 — Ramat Gan, Central District, Israel
• Local Institution - 0020 — Jerusalem, Israel

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.